Paloma Pharmaceuticals is an early-stage drug development company dedicated to addressing diseases characterized by the aberrant up-regulation of the PI3K/Akt/mTOR pathway. Their research targets a wide range of conditions, including cancer, ocular diseases such as macular degeneration and diabetic retinopathy, arthritis, fibrotic diseases like renal and pulmonary fibrosis, CNS disorders including epilepsy and neurodegenerative diseases, antiviral treatments for HIV/AIDS, and skin conditions such as psoriasis, atopic dermatitis, and photodamage.
Paloma Pharmaceuticals has made significant strides in pioneering treatments for these complex diseases, leveraging cutting-edge research to develop innovative therapies. Their work has the potential to impact millions of lives by providing new treatment options for some of the most challenging medical conditions. The company's commitment to scientific excellence and patient care positions them as a notable player in the pharmaceutical industry.
